Bruker Co. (NASDAQ:BRKR) Shares Bought by Assetmark Inc.

Assetmark Inc. grew its position in shares of Bruker Co. (NASDAQ:BRKR) by 23.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,729 shares of the medical research company’s stock after acquiring an additional 331 shares during the quarter. Assetmark Inc.’s holdings in Bruker were worth $119,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. First Horizon Advisors Inc. boosted its position in shares of Bruker by 120.4% in the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after buying an additional 218 shares during the period. Covestor Ltd boosted its position in shares of Bruker by 139.1% in the first quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock worth $34,000 after buying an additional 210 shares during the period. UMB Bank n.a. boosted its position in shares of Bruker by 115.3% in the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after buying an additional 354 shares during the period. Gordian Capital Singapore Pte Ltd purchased a new stake in shares of Bruker in the second quarter worth about $52,000. Finally, GAMMA Investing LLC boosted its position in shares of Bruker by 81.0% in the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock worth $60,000 after buying an additional 388 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Trading Down 5.9 %

NASDAQ:BRKR opened at $51.30 on Monday. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24. The business’s 50 day moving average is $62.60 and its two-hundred day moving average is $65.21. Bruker Co. has a 52 week low of $50.88 and a 52 week high of $94.86. The company has a market cap of $7.78 billion, a PE ratio of 24.66, a P/E/G ratio of 2.46 and a beta of 1.20.

Bruker (NASDAQ:BRKR) last released its earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The firm had revenue of $864.40 million for the quarter, compared to the consensus estimate of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. The company’s quarterly revenue was up 16.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.74 EPS. On average, analysts predict that Bruker Co. will post 2.4 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Barclays reduced their price target on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. TD Cowen reduced their price target on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a report on Wednesday, November 6th. Wells Fargo & Company reduced their price target on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. Citigroup reduced their price target on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Finally, Wolfe Research downgraded Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $79.36.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.